These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36879352)

  • 1. CEUS LI-RADS for diagnosis of hepatocellular carcinoma in individuals without LI-RADS-defined hepatocellular carcinoma risk factors.
    Huang Z; Zhou PP; Li SS; Li K
    Cancer Imaging; 2023 Mar; 23(1):24. PubMed ID: 36879352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.
    Schellhaas B; Görtz RS; Pfeifer L; Kielisch C; Neurath MF; Strobel D
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1036-1044. PubMed ID: 28562394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MR versus CEUS LI-RADS for Distinguishing Hepatocellular Carcinoma from other Hepatic Malignancies in High-Risk Patients.
    Huang Z; Zhou P; Li S; Li K
    Ultrasound Med Biol; 2021 May; 47(5):1244-1252. PubMed ID: 33610338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic Accuracy of CEUS LI-RADS for the Characterization of Liver Nodules 20 mm or Smaller in Patients at Risk for Hepatocellular Carcinoma.
    Huang JY; Li JW; Lu Q; Luo Y; Lin L; Shi YJ; Li T; Liu JB; Lyshchik A
    Radiology; 2020 Feb; 294(2):329-339. PubMed ID: 31793849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contrast-enhanced ultrasound LI-RADS 2017: comparison with CT/MRI LI-RADS.
    Ding J; Long L; Zhang X; Chen C; Zhou H; Zhou Y; Wang Y; Jing X; Ye Z; Wang F
    Eur Radiol; 2021 Feb; 31(2):847-854. PubMed ID: 32803416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences between CEUS LI-RADS and CECT LI-RADS in the diagnosis of focal liver lesions in patients at risk for HCC.
    Wen R; Huang W; Song R; Qin L; Wu Y; Peng Y; Huang X; He Y; Yang H
    BMC Med Imaging; 2023 Sep; 23(1):122. PubMed ID: 37697248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraindividual Comparison of Contrast-Enhanced Ultrasound Using Perfluorobutane With Modified Criteria Versus CT/MRI LI-RADS Version 2018 for Diagnosing HCC in High-Risk Patients.
    Li L; Mao S; Wang J; Zheng W; Shen J; Clevert DA; Zhou J
    AJR Am J Roentgenol; 2023 May; 220(5):682-691. PubMed ID: 36382914
    [No Abstract]   [Full Text] [Related]  

  • 8. Contrast-enhanced ultrasound Liver Imaging Reporting and Data System: Lights and shadows in hepatocellular carcinoma and cholangiocellular carcinoma diagnosis.
    Vidili G; Arru M; Solinas G; Calvisi DF; Meloni P; Sauchella A; Turilli D; Fabio C; Cossu A; Madeddu G; Babudieri S; Zocco MA; Iannetti G; Di Lembo E; Delitala AP; Manetti R
    World J Gastroenterol; 2022 Jul; 28(27):3488-3502. PubMed ID: 36158272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contrast-Enhanced Ultrasound Using Perfluorobutane: Impact of Proposed Modified LI-RADS Criteria on Hepatocellular Carcinoma Detection.
    Li L; Zheng W; Wang J; Han J; Guo Z; Hu Y; Li X; Zhou J
    AJR Am J Roentgenol; 2022 Sep; 219(3):434-443. PubMed ID: 35441534
    [No Abstract]   [Full Text] [Related]  

  • 10. Diagnostic efficacy of contrast-enhanced ultrasound versus MRI Liver Imaging Reporting and Data System (LI-RADS) for categorising hepatic observations in patients at risk of hepatocellular carcinoma.
    Li S; Zhou L; Chen R; Chen Y; Niu Z; Qian L; Fang Y; Xu L; Xu H; Zhang L
    Clin Radiol; 2021 Feb; 76(2):161.e1-161.e10. PubMed ID: 33198943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor size-based validation of contrast-enhanced ultrasound liver imaging reporting and data system (CEUS LI-RADS) 2017 for hepatocellular carcinoma characterizing.
    Pan JM; Chen W; Zheng YL; Cheng MQ; Zeng D; Huang H; Huang Y; Xie XY; Lu MD; Kuang M; Hu HT; Chen LD; Wang W
    Br J Radiol; 2021 Oct; 94(1126):20201359. PubMed ID: 34545763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LI-RADS-CEUS - Proposal for a Contrast-Enhanced Ultrasound Algorithm for the Diagnosis of Hepatocellular Carcinoma in High-Risk Populations.
    Schellhaas B; Wildner D; Pfeifer L; Goertz RS; Hagel A; Neurath MF; Strobel D
    Ultraschall Med; 2016 Dec; 37(6):627-634. PubMed ID: 27486793
    [No Abstract]   [Full Text] [Related]  

  • 13. LR-M Observations on Contrast-Enhanced Ultrasound: Detection of Hepatocellular Carcinoma Using Additional Features in Comparison With Current LI-RADS Criteria.
    Xian MF; Huang Y; Xie WX; Pan KM; Zeng D; Huang H; Li MD; Xie XY; Kuang M; Lu MD; Chen LD; Wang W
    AJR Am J Roentgenol; 2022 Jul; 219(1):76-85. PubMed ID: 34910538
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of contrast-enhanced ultrasound LI-RADS version 2017: application on 271 liver nodules in individuals with non-alcoholic steatohepatitis.
    Huang Z; Zhou P; Li S; Li K
    Eur Radiol; 2022 Oct; 32(10):7146-7154. PubMed ID: 35639147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.
    Terzi E; Iavarone M; Pompili M; Veronese L; Cabibbo G; Fraquelli M; Riccardi L; De Bonis L; Sangiovanni A; Leoni S; Zocco MA; Rossi S; Alessi N; Wilson SR; Piscaglia F;
    J Hepatol; 2018 Mar; 68(3):485-492. PubMed ID: 29133247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between M-score and LR-M in the reporting system of contrast-enhanced ultrasound LI-RADS.
    Chen LD; Ruan SM; Lin Y; Liang JY; Shen SL; Hu HT; Huang Y; Li W; Wang Z; Xie XY; Lu MD; Kuang M; Wang W
    Eur Radiol; 2019 Aug; 29(8):4249-4257. PubMed ID: 30569182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic performance of intravascular perfusion based contrast-enhanced ultrasound LI-RADS in the evaluation of hepatocellular carcinoma.
    Zuo D; Yang K; Wu S
    Clin Hemorheol Microcirc; 2021; 78(4):429-437. PubMed ID: 33867358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival?
    Yang J; Huang JY; Chen X; Ling WW; Luo Y; Shi YJ; Liu JB; Lu Q; Lyshchik A
    Eur Radiol; 2021 Aug; 31(8):6397-6405. PubMed ID: 33492470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Value of CEUS LI-RADS combined with AFP in early diagnosis of hepatocellular carcinoma in low- and high-risk patients.
    Wu Y; Chen Y; Wei L; Ding Z; Zhao S; Bao S; Tang J; Li H; Liu J; Zhu S
    J Cancer Res Ther; 2024 Aug; 20(4):1274-1283. PubMed ID: 38958652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interreader agreement and validation of contrast-enhanced ultrasound liver imaging reporting and data system.
    Li J; Ling W; Chen S; Ma L; Yang L; Lu Q; Luo Y
    Eur J Radiol; 2019 Nov; 120():108685. PubMed ID: 31606712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.